Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JHPCYDrugs in Pipeline
30
Phase 3 Programs
14
Upcoming Catalysts
5
Next Catalyst
May 15, 2026
19dMarket Overview
Stock performance and key metrics
5 upcoming, 0 past
SHR-1209
Primary Hypercholesterolemia
Remimazolam Tosilate
General Anesthesia
Propofol
Anesthesia for Elective Surgery Patients
VC005 tablets
Active Ankylosing Spondylitis
SHR6390
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Pyrotinib
HER2-positive Breast Cancer
JSKN016 Injection
Triple Negative Breast Cancer
SHR7280 tablets
Uterine Fibroids With Menorrhagia
SHR-A1811
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
apatinib
Non-Small-Cell Lung Cancer
Hetrombopag Olamine
Severe Aplastic Anemia
SHR0302
Rheumatoid Arthritis
HR17031 injection
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
Tegileridine Fumarate lnjection
Abirritation in the ICU
Bupivacaine Liposome Injection
Local Analgesia Via Nerve Block
SHR4640 ；Febuxostat
Primary Gout and Hyperuricemia
HRS-9190
Neuromuscular Blockade
HR19042 Capsules
IgA Nephropathy
FRSW117
Severe Hemophilia A
HRS-4508 tablet
Lung Cancer
Famitinib
Colorectal Cancer
SHR-1210
Nasopharyngeal Carcinoma
AZD4205
Nonsmall Cell Lung Cancer
SHR-A1811 Injection
Recurrent or Metastatic Cervical Cancer
HS-20093 for Injection
Prostate Cancer
KN046
Esophageal Squamous Cell Carcinoma
SHR-3167
Type 2 Diabetes Mellitus
SHR-4394
Prostate Cancer
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Advanced Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
Remimazolam Tosilate | Phase 3 | General Anesthesia | - | - |
Propofol | Phase 3 | Anesthesia for Elective Surgery Patients | - | - |
VC005 tablets | Phase 3 | Active Ankylosing Spondylitis | - | - |
SHR6390 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | - | - |
Pyrotinib | Phase 3 | HER2-positive Breast Cancer | - | - |
JSKN016 Injection | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR7280 tablets | Phase 3 | Uterine Fibroids With Menorrhagia | - | - |
SHR-A1811 | Phase 3 | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | - | - |
apatinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Hetrombopag Olamine | Phase 3 | Severe Aplastic Anemia | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
Tegileridine Fumarate lnjection | Phase 2 | Abirritation in the ICU | - | - |
Bupivacaine Liposome Injection | Phase 2 | Local Analgesia Via Nerve Block | - | - |
SHR4640 ；Febuxostat | Phase 2 | Primary Gout and Hyperuricemia | - | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - | - |
HR19042 Capsules | Phase 2 | IgA Nephropathy | - | - |
FRSW117 | Phase 2 | Severe Hemophilia A | - | - |
HRS-4508 tablet | Phase 2 | Lung Cancer | - | - |
Famitinib | Phase 2 | Colorectal Cancer | - | - |
SHR-1210 | Phase 2 | Nasopharyngeal Carcinoma | - | - |
AZD4205 | Phase 2 | Nonsmall Cell Lung Cancer | - | - |
SHR-A1811 Injection | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
HS-20093 for Injection | Phase 2 | Prostate Cancer | - | - |
KN046 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
SHR-4394 | Phase 2 | Prostate Cancer | - | - |
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |